DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc > Stock price could hit $5.00US by end of week.

<< Previous

Bullboard Posts

Next >>

Comment by TrueNorth911on Apr 10, 2019 11:24pm

75 Views

Post# 29610786

RE:RE:RE:RE:Stock price could hit $5.00US by end of week.

Early is how I would characterize it.... but don't forget they were under immense pressure to raise funds to continue the trials, and to kick-off CKD trials.... and we all know that was NOT going to happen in Canada on TSX-V. No way they were going to raise $20M Cdn! in Canada. Be real.

I know it sounds like a broken record...but it needs to play itself out. We're still early in the trial cycle. End of year will be here before we know it....hopefully with a pleasant Xmas for all.

<< Previous

Bullboard Posts

Next >>

Parliament looks for your word on potential Chinese-made EV tariffs